vs
Side-by-side financial comparison of GCL Global Holdings Ltd (GCL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $98.7M, roughly 2.0× GCL Global Holdings Ltd). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-5.2M).
GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GCL vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $98.7M | $196.9M |
| Net Profit | $-5.1M | — |
| Gross Margin | 11.0% | 79.5% |
| Operating Margin | -6.7% | 1.2% |
| Net Margin | -5.2% | — |
| Revenue YoY | — | 5.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.04 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $196.9M | ||
| Q3 25 | $98.7M | $179.5M | ||
| Q2 25 | $142.1M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $36.1M | $168.6M | ||
| Q2 24 | — | $178.0M | ||
| Q1 24 | — | $167.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.1M | $5.4M | ||
| Q2 25 | $5.6M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.9M | $-143.5M | ||
| Q2 24 | — | $18.9M | ||
| Q1 24 | — | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | 11.0% | 80.9% | ||
| Q2 25 | 15.0% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 16.2% | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | -6.7% | 3.5% | ||
| Q2 25 | 2.3% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -5.6% | -82.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 7.9% |
| Q4 25 | — | — | ||
| Q3 25 | -5.2% | 3.0% | ||
| Q2 25 | 3.9% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.2% | -85.1% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-0.04 | $0.12 | ||
| Q2 25 | $0.05 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $238.4M |
| Total DebtLower is stronger | $52.0M | $372.2M |
| Stockholders' EquityBook value | $33.1M | $693.1M |
| Total Assets | $159.9M | $1.3B |
| Debt / EquityLower = less leverage | 1.57× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $238.4M | ||
| Q3 25 | $16.6M | $246.3M | ||
| Q2 25 | $18.2M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $2.7M | $453.8M | ||
| Q2 24 | — | $404.2M | ||
| Q1 24 | — | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | $52.0M | $376.7M | ||
| Q2 25 | $11.9M | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $693.1M | ||
| Q3 25 | $33.1M | $727.2M | ||
| Q2 25 | $35.9M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $15.9M | $749.6M | ||
| Q2 24 | — | $879.3M | ||
| Q1 24 | — | $892.2M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | $159.9M | $1.3B | ||
| Q2 25 | $101.6M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $49.6M | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | 1.57× | 0.52× | ||
| Q2 25 | 0.33× | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $43.7M |
| Free Cash FlowOCF − Capex | $-5.2M | $43.5M |
| FCF MarginFCF / Revenue | -5.3% | 22.1% |
| Capex IntensityCapex / Revenue | 0.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $43.7M | ||
| Q3 25 | $-4.8M | $60.8M | ||
| Q2 25 | $-10.3M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $6.1M | $53.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $49.1M |
| Q4 25 | — | $43.5M | ||
| Q3 25 | $-5.2M | $57.0M | ||
| Q2 25 | $-10.5M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M | ||
| Q1 24 | — | $46.3M |
| Q4 25 | — | 22.1% | ||
| Q3 25 | -5.3% | 31.7% | ||
| Q2 25 | -7.4% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.4% | 2.2% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | -1.84× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GCL
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
